Study S002273

A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide Plus a Reduced Calorie Diet and Increased Physical Activity in Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07220629
Acronym: RESOLVE-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 82
Start: 2025-10-02
Primary completion: 2026-08-21
Lead sponsor: Rezera (formerly NodThera Limited)
Conditions: Obesity
Interventions: DRUG:NT-0796; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs. [Baseline to Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.